Kazakhstan vs United States: The number of people with susceptibility test result for rifampicin
Kazakhstan
5,121
in 2021
United States
4,814
in 2021
Kazakhstan rank
28th
United States rank
30th
The number of people with susceptibility test result for rifampicin over time
- Kazakhstan
- United States
How they compare
Kazakhstan currently reports 5,121 against 4,814 in United States, a difference of 307.
That makes Kazakhstan's figure about 1.1 times United States's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was United States ahead.
Kazakhstan ranks 28th and United States ranks 30th of 155 countries.
Kazakhstan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kazakhstan | United States | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,272 | 5,218 | 54 | Kazakhstan |
| 2020s | 4,990 | 4,592 | 397.5 | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Kazakhstan or United States?
- Kazakhstan, at 5,121 against 4,814 in United States as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Kazakhstan and United States?
- 307, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and United States?
- 5 years are reported by both, from 2017 to 2021.
- How do Kazakhstan and United States rank globally for the number of people with susceptibility test result for rifampicin?
- Kazakhstan ranks 28th and United States ranks 30th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.